Arrowhead Pharmaceuticals, Inc.(ARWR)

$87.11—

Chart

Arrowhead Pharmaceuticals, Inc.(ARWR)

NASDAQ

$87.11—

Chart Studio

ARWR(ARWR)

ARWR

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-1.52

Nov 24, 2026 · Reports after close

Revenue Estimate

$72M

FY2030E EPS$4.41

Analyst Sentiment

Wall St. Consensus

Buy

22 analysts·High coverage

Score

16 Buy (73%)6 Hold (27%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

1673%

Hold

627%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$46.00

-47.2%

Consensus

$117.50

+34.9%

Bull

$126.00

+44.6%

12-Month Target Range22 analysts

$46.00$117.50$126.00

Current $87.11Consensus

Current Price

$87.11

Upside to Consensus

$30.39

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-28.20%

EPS—

FY2028

Rev+122.42%

EPS—

FY2029

Rev+50.53%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$477M	$343M	$762M	$1.15B	$2.04B
Low	$420M	$143M	$345M	$716M	$1.27B
High	$594M	$600M	$1.57B	$1.99B	$3.54B
EBITDA Avg	$-301M	$-216M	$-481M	$-725M	$-1.29B
Low	$-375M	$-379M	$-990M	$-1.26B	$-2.24B
High	$-265M	$-90M	$-218M	$-452M	$-805M
EBIT Avg	$-317M	$-228M	$-506M	$-762M	$-1.36B
Low	$-394M	$-399M	$-1.04B	$-1.32B	$-2.35B
High	$-279M	$-95M	$-229M	$-476M	$-847M
Net Income Avg	$-497M	$-690M	$-432M	$-98M	$589M
Low	$-688M	$-886M	$-699M	$-192M	$301M
High	$-328M	$-331M	$19M	$-50M	$1.15B
EPS Avg	$-3.51	$-4.72	$-2.50	$-0.74	$4.41
Low	$-5.14	$-6.62	$-5.23	$-1.44	$2.25
High	$-2.45	$-2.47	$0.14	$-0.38	$8.61
Analysts (Rev / EPS)	10 / 11	11 / 11	8 / 7	4 / 2	4 / 4

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027
Revenue Avg	$72M	$37M	$40M	$36M	$138M
Low	$5M	$18M	$9M	$8M	$32M
High	$192M	$53M	$86M	$78M	$302M
EBITDA Avg	$-45M	$-23M	$-25M	$-23M	$-87M
Low	$-121M	$-33M	$-54M	$-49M	$-190M
High	$-3M	$-11M	$-6M	$-5M	$-20M
EBIT Avg	$-48M	$-24M	$-26M	$-24M	$-92M
Low	$-128M	$-35M	$-57M	$-52M	$-200M
High	$-3M	$-12M	$-6M	$-6M	$-22M
Net Income Avg	$-219M	$-202M	$-200M	$-207M	$-122M
Low	$-413M	$-234M	$-507M	$-525M	$-310M
High	$-48M	$-165M	$-836,505	$-865,267	$-510,531
EPS Avg	$-1.52	$-1.41	$-1.40	$-1.44	$-0.85
Low	$-2.88	$-1.63	$-3.54	$-3.66	$-2.16
High	$-0.34	$-1.15	$-0.01	$-0.01	$-0.00
Analysts (Rev / EPS)	9 / 10	3 / 4	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Aug 6, 2026H.C. Wainwright

Arrowhead price target raised to $120 from $115 at H.C. Wainwright

Target:$120.00

+40.2%from $85.61

Aug 5, 2026Stifel Nicolaus

Arrowhead price target raised to $104 from $98 at Stifel

Target:$104.00

+16.1%from $89.59

Jul 27, 2026H.C. Wainwright

Arrowhead price target raised to $115 from $100 at H.C. Wainwright

Target:$115.00

+34.3%from $85.60

Jul 23, 2026Morgan Stanley

Arrowhead price target raised to $120 from $100 at Morgan Stanley

Target:$120.00

+35.8%from $88.38

Jul 23, 2026Piper Sandler

Arrowhead price target raised to $126 from $110 at Piper Sandler

Target:$126.00

+42.1%from $88.70

Jul 22, 2026Chardan Capital

Arrowhead price target raised to $115 from $90 at Chardan

Target:$115.00

+26.3%from $91.03

Jul 13, 2026Stifel Nicolaus

Arrowhead initiated with a Buy at Stifel

Target:$98.00

+32.2%from $74.11

May 13, 2026Bernstein

Arrowhead price target raised to $46 from $35 at Bernstein

Target:$46.00

-41.8%from $79.04

May 8, 2026Chardan Capital

Arrowhead price target raised to $90 from $80 at Chardan

Target:$90.00

+15.5%from $77.95

Apr 21, 2026Morgan Stanley

Arrowhead upgraded to Overweight from Equal Weight at Morgan Stanley

Target:$100.00

+44.4%from $69.25

Feb 6, 2026Morgan Stanley

Arrowhead price target lowered to $78 from $81 at Morgan Stanley

Target:$78.00

+17.1%from $66.64

Jan 27, 2026Robert W. Baird

Morgan Stanley on Arrowhead Pharma (ARWR): 'we are encouraged by the on track progress for the ARO-DIMER-PA program'

Target:$81.00

+20.9%from $67.02

Jan 21, 2026H.C. Wainwright

Arrowhead price target raised to $100 from $85 at H.C. Wainwright

Target:$100.00

+45.3%from $68.80

Jan 13, 2026UBS

'Arrowhead Pharma (ARWR) Raises $930 Million to Launch Redemplo'; PT Raised at Piper Sandler

Target:$110.00

+61.7%from $68.03

Jan 13, 2026Piper Sandler

Arrowhead price target raised to $110 from $100 at Piper Sandler

Target:$110.00

+66.8%from $65.93

Jan 7, 2026Morgan Stanley

Arrowhead price target raised to $81 from $48 at Morgan Stanley

Target:$81.00

+14.4%from $70.81

Jan 7, 2026Chardan Capital

Arrowhead price target raised to $80 from $60 at Chardan

Target:$80.00

+13.0%from $70.81

Jan 2, 2026Tudor Pickering

Arrowhead Pharma (ARWR) PT Raised at Bernstein Ahead of Obesity Data Update

Target:$35.00

-47.3%from $66.39

Dec 31, 2025Bernstein

Arrowhead price target raised to $35 from $17 at Bernstein

Target:$35.00

-48.0%from $67.25

Dec 17, 2025Piper Sandler

Arrowhead price target raised to $100 from $70 at Piper Sandler

Target:$100.00

+54.7%from $64.66

Dec 11, 2025RBC Capital

Arrowhead price target raised to $80 from $52 at RBC Capital

Target:$80.00

+16.1%from $68.91

Dec 2, 2025H.C. Wainwright

Arrowhead price target raised to $85 from $80 at H.C. Wainwright

Target:$85.00

+51.1%from $56.25

Nov 26, 2025Morgan Stanley

Arrowhead price target raised to $48 from $45 at Morgan Stanley

Target:$48.00

+2.6%from $46.79

Nov 29, 2024Bernstein

Arrowhead Pharma (ARWR) PT Lowered to $24 at Bernstein SocGen Group

Target:$24.00

-7.0%from $25.81

Nov 27, 2024Loop Capital Markets

Chardan Capital Markets Reiterates Buy Rating on Arrowhead Pharma (ARWR)

Target:$60.00

+365.1%from $12.90

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance